Calidi Biotherapeutics Q1 2026 net loss narrows to $4.4M; cash $6.6M, CLD-401 IND on track

Calidi Biotherapeutics, Inc.

2026-Q1 EPS reported -$0.43

Net loss attributable to common shareholders: $4.4M ($0.43/shr) vs $5.0M ($2.21/shr) in Q1 2025.
Cash and restricted cash $6.8M as of Mar 31, 2026; up from $5.8M at Dec 31, 2025.
G&A expenses fell $1.0M to $1.6M; R&D expenses rose to $2.6M from $2.4M.
CLD-401 IND submission expected by end of 2026; AACR data showed T, NK, and γδ T-cell activation.
Entered partnership with TransferAI to use AI platform to streamline CLD-401 IND submission.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.